Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.

International journal of molecular sciences - 5 Sept 2023

Zamora Irene, Freeman Michael R, Encío Ignacio J, Rotinen Mirja

Abstract excerpt

Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PC) that commonly emerges through a transdifferentiation process from prostate adenocarcinoma and evades conventional therapies. Extensive molecular research has revealed factors that drive lineage plasticity, uncovering novel therapeutic targets to be explored. A diverse array of targeting agents is currently under...

Topics

Join the communities discussing this publication.

Carcinoma, Neuroendocrine
Cell Line, Tumor
Neuroendocrine Tumor Research Advances
Phenotype
Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Prostatic Neoplasms

Radiopharmaceutical Chemistry and Applications

Source

Open in PubMed Open full text

Identifiers

PMID: 37761978
DOI: 10.3390/ijms241813673
PMCID: PMC10531052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.PMID 37761978Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer ProgressionSemantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

Molecular model for neuroendocrine prostate cancer progressionSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Cellular plasticity and the neuroendocrine phenotype in prostate cancer.Semantic proximity Read ↗

Therapy considerations in neuroendocrine prostate cancer: what next?Semantic proximity Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Neuroendocrine differentiation of prostate cancer.Semantic proximity Read ↗

The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage PlasticitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.